

Association of Two Methylenetetrahydrofolate Reductase Polymorphisms (rs1801133, rs1801131) with the Risk of Type 2 Diabetes in South-East of Iran

Maryam Poodineh¹, Ramin Saravani^{*2,3}, Mahboubeh Mirhosseini¹, Saman Sargazi²

Abstract

Background: DNA methylation has been linked to the development and progression of multiple disorders including T2D. One significant enzyme involved in DNA methylation is methylene tetrahydrofolate reductase (*MTHFR*). This study was designed to evaluate the association between rs1801133 and rs1801131 polymorphisms, located in the *MTHFR*, and T2D in an Iranian population.

Methods: Blood samples from 151 patients with T2D and 136 healthy individuals were collected and DNA was extracted using the salting out method. Variants were genotyped using amplification tetra-refractory mutation system-polymerase chain reaction analysis. The data were analyzed via independent sample t-test and χ^2 tests.

Results: The rs1801131 A/C polymorphism significantly increased the risk of T2D in codominant heterozygous AC (P=0.008), homozygous CC (P=0.01), and recessive CC (P=0.001) genotypes. Significant correlations were found regarding rs1801133 T/C gene polymorphism and the risk of T2D in codominant heterozygous TC (P=0.001), homozygote CC (P=0.001), and recessive CC (P=0.0001) models. The presence of the C allele is a potential risk factor for T2D for rs1801133 T/C (P=0.001) and rs1801131 A/C (P=0.04) polymorphisms.

Conclusions: Both the rs1801133 T/C and rs1801131 A/C *MTHFR* polymorphisms significantly increased the risk of T2D in our population. Further studies in other ethnicities are necessary to verify our findings.

Keywords: Gene Polymorphism, *MTHFR*, Type 2 diabetes.

Introduction

Diabetes mellitus (DM), the most common metabolic endocrine disorder, is characterized by increased glucose levels and disturbed carbohydrate, fat, and protein metabolism (1). Generally, DM is categorized into several subtypes, the most common of which are types 1 and 2 (T1D and T2D, respectively) (2). Type 2 diabetes is most common, gradually progresses with age, and unlike type 1, does not result in ketoacidosis (3). The prevalence of DM in western Asia, including Iran, was 11.37 % in 2011, and is expected to increase (4). Type 2 diabetes is more prevalent in developed countries,

where it is a major health problem, than in undeveloped countries (5). Female gender, high blood pressure, increased basic metabolic index (BMI), and positive family history are independent risk factors for DM (6). Type 2 diabetes is a polygenic and multifactorial disease as various genetic loci play crucial roles in its development (7). Single-nucleotide polymorphisms (SNPs) have been identified in several genes associated with the increased risk of T2D (8).

The methylene tetrahydrofolate reductase gene (*MTHFR*) is located at the end of the short arm of

1: Department of Biology, Payame Noor University of Taft, Yazd, Iran.

2: Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

3: Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

*Corresponding author: Ramin Saravani; Tel: +98-543329892; Fax: +98-543329892; E-mail: saravanimiramin@yahoo.com.

Received: 19 Feb, 2019; Accepted: 3 Feb, 2019

chromosome 1 and has 11 exons. Based on reads per kilo base per million mapped reads (RPKM) information, *MTHFR* expression differs between organs, being higher in the lung (RPKM 7.5) and thyroid (RPKM 7.2) than in other tissues (9). The active *MTHFR* enzyme plays a central role in folate metabolism and converts 5, 10-methylene tetrahydrofolate to 5-ethyltetrahydrofolate, the dominant form of folate in the blood (10). Homocysteine is an amino acid that contains sulfur formed during methionine metabolism. Homocysteine converts to methionine by receiving one methyl group from 5-methyltetrahydrofolate, which also plays a role in the biosynthesis of S-adenosyl methionine (11). Earlier studies have established that insulin plasma levels affect homocysteine metabolism through the effective activation of enzymes involved in homocysteine metabolism, such as *MTHFR* (12, 13). rs1801133 (677C>T, MAF=0.31) and rs1801131 (1298A/C, MAF=0.29) are two common polymorphisms located within *MTHFR* (14). Studies in China showed a significant association between these two missense genetic variants and T2D (15). Basically, *MTHFR* polymorphisms reduce the frequency of mutations in *MTHFR*, causing decreased enzymatic activity in some races (16); in some cases, enzymatic activity is reduced by up to 50% (17, 18). Also, hypermethylation in the *MTHFR* promoter region is linked with complications of DM (19) and the susceptibility to essential hypertension,

cardiovascular diseases, and homocysteinemia (20). Kheradmand et al. showed that genetic mutations in *MTHFR* coding regions are significantly higher in patients with insulin resistance than in those without (21).

To our knowledge, a possible link between rs1801133 T/C and rs1801131 A/C polymorphisms and the risk of developing T2D has not been investigated in the southeast Iranian population, therefore we aimed to investigate this association in various inheritance models.

Materials and methods

Subjects

The study protocol was approved by the Ethics Committee of the Payam Noor University of Taft, Yazd (Grant No: 3713). One hundred thirty-six T2D patients referring to the diabetes center of Boo-Ali Hospital in Zahedan and 151 healthy individuals with normal blood glucose levels and no history of systemic diseases or family relationships with T2D patients were enrolled. The inclusion criteria included blood glucose concentration greater than 126 mg/dL, hemoglobin A1C greater than 6.5%, and agreement of at least two endocrinologists. All participants comprehended the informed consent forms and the demographic information including age, sex, body mass index (BMI), fasting blood glucose (FBS), triglyceride (TG) and total cholesterol (TC), and these were collected from both groups (Table 1).

Table 1. Association between clinicopathological characteristics of T2D patients and healthy individuals.

Parameters evaluated	T2D (n=136) (n±SD)	Controls (n=151) (n±SD)	P Value
Sex female/male	94/42	101/50	0.39
Age (year)	52.16±9.3	50.53±9.02	0.08
FBS (mg/dl)	182.72±68	95.16±10.37	<0.001
TG (mg/dl)	148.34±81	138±64	0.41
TC (mg/dl)	171/36±53	165.01±45	0.24

DNA extraction, primer design, and genotyping

Four mL of venous whole blood were collected for DNA extraction (2 mL in 0.5 M EDTA-containing tubes) and biomedical parameters (2 mL in blood-drawing tubes containing an integral serum-separating barrier gel). DNA was extracted using the salting out method (22). The quality and the quantity

of extracted DNA was assessed using 2% agarose gel electrophoresis and UV spectrophotometry. The tetra-primer amplification refractory mutation system (Tetra-ARMS) method was used to genotype *MTHFR* polymorphisms rs1801131 A/C and rs1801133 T/C. The specific primers were designed using BatchPrimer3 (23) (Table 2).

Table 2. The primers used for detection of rs1801131 A/C and rs1801133 T/C polymorphisms.

Gene polymorphism	Primers	Sequence (5' to 3')
rs1801131 A/C	FO	GCAGAAGAAGTTTGCATGCTTGTGGTTG
	RO	ACTTACCCTTCTCCCTTTGCCATGTCCA
	FI	GTGGGGGGAGGAGCTGACCAGTGAGGA
	RI	GGTAAAGAACGAAGACTTCAAAGACACCTG
rs1801133 C/T	FO	CATATCAGTCATGAGCCCAGCCACTCAC
	RO	AGGAGATCTGGGAAGAACCAGCGAACTC
	FI	TTGAAGGAGAAGGTGTCTGCGGGCGT
	RI	CAAAGAAAAGCTGCGTGATGATGAAATAGG

FO: Forward outer; RO: Reverse outer; FI: Forward inner; RI: Reverse inner.

For each PCR, 0.5 µL (10 ng/mL) of each primer (Pishgaman Co.Iran), 12 µL of Master Mix (Ampliqon, Denmark), 2 µL (~1ng/mL) of genomic DNA, and 10 µL of DNase-free distilled water (Parstous Biotech Co., Iran) were mixed to a final volume of 25

µL. The tetra ARMS-PCR temperature/time schedule is presented in *Table 3*. At least 40% of the PCR products were evaluated on 2% agarose gels using a UV transilluminator set at 254 nm (Ultra-Lum Electronic UV Transilluminator, USA).

Table 3. PCR conditions for tetra-ARMS PCR genotyping of rs1801131 A/C and rs1801133 T/C polymorphisms.

Polymorphism	Cycle	Temperature (°C)	Time (minutes)	Number of cycles
rs1801133 T/C	Initial Denaturation	95	5:00	1
	Denaturation	95	0:30	35
	Annealing	66	0:30	
	Extension	72	0:45	
	Final extension	72	05:00	1
rs1801131 A/C	Initial Denaturation	95	05:00	1
	Denaturation	95	0:30	35
	Annealing	54	0:30	
	Extension	72	0:45	
	Final extension	72	05:00	1

Statistical analyses

The results were analyzed using SPSS V.16 for Windows (SPSS Inc., Chicago, IL, USA). An independent t-test was used to compare the data between the patient and control groups. Chi-square and logistic regression were used to determine the relationship between T2D and the SNPs. P values less than 0.05 were considered significant.

Results

Patients and controls were matched in terms of age and sex. No significant differences were found between the two groups for either parameter while the mean glucose level

significantly differed between the two groups ($P < 0.05$, Table 1). Because the patients in this study were monitored by endocrinologists and receiving prescriptions, no significant differences were found between the two groups for either triglyceride or total cholesterol ($P > 0.05$ for both, *Table 1*). Comparison of the frequency of *MTHFR* rs1801131 A/C polymorphism between T2D patients and healthy controls revealed that in the codominant model genotype CC (OR = 3.03, 95% CI, (1.25-7.36), $P = 0.01$) and in the recessive model genotype CC (OR = 5.8, 95% CI, (2.80-12.31), $P = 0.001$) and allele C (OR = 1.37, 95% CI (0.99-1.91), $P = 0.04$) of this polymorphism were risk factors for T2D (Table 4).

Table 4. Genotypic and allelic frequencies of *MTHFR* polymorphism (rs180131 A/C) in T2D patients and control subjects.

Inheritance Models	Genotypes/Alleles	T2D, n (%)	Control, n (%)	OR (95%CI)	P-Value
Codominant	AA	29 (21)	22 (14)	1.00	
	AC	67 (50)	119 (79)	0.42 (0.22-0.8)	0.08
	CC	40 (29)	10 (7)	3.03 (1.25-7.36)	0.01
Recessive	AA+ AC	40 (000)	10 (000)	1.00	
	CC	96 (000)	141 (000)	5.8 (2.80-12.31)	0.001
	A	125	163	1.00	
	C	147	139	1.37 (0.99-1.91)	0.04

Regarding the rs1801133 (T>C) polymorphism, we found that inheritance models of codominant heterozygote TC (OR = 7.39, 95% = CI (4.21-12.97), P = 0.001), homozygous CC (OR = 7.78, 95% = CI (3.40-17.79), P = 0.001), and recessive

CC (OR: 3.17, 95% = CI (1.46-6.88, P = 0.001) genotypes were significantly associated with T2D susceptibility. Also, the presence of allele C (OR = 2.77, 95% = CI (1.87-4.09) P = 0.001) could be a risk factor for T2D (Table 5).

Table 5. Genotypic and allelic frequencies of *MTHFR* polymorphism (rs180133 T/C) in T2D patients and control subjects.

Inheritance Models	Genotypes/Alleles	T2D, n (%)	Control, n (%)	OR (95%CI)	P-Value
Codominant	TT	35 (26)	109 (72)	1.00	
	TC	76 (56)	32 (21)	7.39 (4.21-12.97)	0.001
	CC	25 (18)	10 (7)	7.78 (3.40-17.79)	0.001
Recessive	TT+TC	25 (18)	10 (7)	1.00	
	CC	111 (82)	141 (93)	3.17 (1.46-6.88)	0.001
	T	174 (64)	251(83)	1.00	
	C	98 (36)	51(17)	2.77 (1.87-4.09)	0.001

Discussion

Studies have shown that both hyperglycemia and insulin resistance trigger a cascade of responses, which ultimately leads to enhanced DNA methylation in various tissues (24). DNA methylation has attracted much attention in recent years and occurs under various physiochemical conditions. To date, DNA methylation has been well demonstrated in DM (25). Hyperinsulinemia affects *MTHFR* activity, while the high level of homocysteine, due to mutations in *MTHFR*, is associated with insulin resistance (26). The relationship between *MTHFR* C677T and A1298C polymorphisms and complications of T2D has been reported in an Emirati population (16), but no study has investigated a possible link

between these two variants and T2D susceptibility in the Iranian population.

In our study, we found that the presence of C allele increased the risk of T2D progression and development in both *MTHFR* polymorphisms. Also, the evaluation of codominant, recessive models indicated that the rs1801131 and rs1801133 polymorphisms were significantly linked with T2D susceptibility in our population. In contrast to our findings, Zhong et al. (2013) reported no significant association between the rs1801133 polymorphism and risk of T2D (18). Raza et al. (2017) reported that the rs1801133 polymorphism might also be correlated with dyslipidemia development in T2D patients (27).

Furthermore, Raza et al. (2012) found a significant correlation between the rs1801131 polymorphism and T2D in an Indian population (28). Mtiraoui et al. (2007) reported that CT and TT genotypes in the rs1801133 locus indicated increased risk of T2D, while no significant association was found between the rs1801131 polymorphism and DM in a Tunisian population (29). Zhong et al. (2013) reported that the allele C of rs1801133 locus has a protective effect against T2D (18), which agreed with our findings in this work. Additionally, our results are consistent with those reported by Yan et al. (2013) on a Chinese population sample, indicating that rs1801131 was associated with an increased risk of DM (30). Zhou et al. (2014), inferred that the rs1801131 CC genotype significantly increased the risk of ischemic stroke, indicating that *MTHFR* polymorphisms might influence susceptibility to several disorders by significantly altering total homocysteine levels and *MTHFR* enzymatic activity (31). The differences

in the results obtained in the current work and those of other investigations could be attributed to differences in race, genetics, geographic area, and lifestyle, as well as the limited sample size. Further studies with a larger cohort in different populations could provide more details on the relationship between these two non-synonymous *MTHFR* SNPs and T2D.

We conclude that the *MTHFR* rs1801131 A/C and rs1801133 T/C polymorphisms might be genetic biomarkers for T2D progression and development in this Iranian population sample. However, the authors suggest further investigation on a larger sample and other ethnicities to verify these results.

Acknowledgment

This work is financially supported by Payame Noor University of Taft, Yazd, Iran (Grant No. 3-2.3.3713). The authors acknowledge and thank the staff of Cellular and Molecular Research Center of Zahedan University of Medical Sciences.

References

1. Alberti, K.G.M.M. and P.f. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. *Diagnosis and classification of diabetes mellitus*. *Diabetic Med*. 1998; 15(7):539-553.
2. Association, A.D., *Diagnosis and classification of diabetes mellitus*. *Diabetes care*. 2014;37:81-S90.
3. Jain, S.K., R. McVie, and J.A. Bocchini Jr, Hyperketonemia (ketosis), oxidative stress and type 1 diabetes. *Pathophysiology*. 2006; 13(3): 163-170.
4. Esteghamati, A., et al., Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011. *Diabetes Res Clin Pract*. 2014; 103(2): 319-327.
5. Nolan, C.J., P. Damm, and M. Prentki, Type 2 diabetes across generations: from pathophysiology to prevention and management. *The Lancet*. 2011; 378(9786):169-181.
6. Lotfi, M.H., H. Saadati, and M. Afzali, Prevalence of diabetes in people aged ≥ 30 years: the results of screen-ing program of Yazd Province, Iran, in 2012. *J Res health Sci*. 2013; 14(1): 88-92.
7. Olokoba, A.B., O.A. Obateru, and L.B. Olokoba, Type 2 diabetes mellitus: a review of current trends. *Oman medical journal*. 2012; 27(4): 269.
8. Al-Daghri, N.M., et al., Association between type 2 diabetes mellitus-related SNP variants and obesity traits in a Saudi population. *Mol Biol Rep*. 2014; 41(3): 1731-1740.
9. Fagerberg, L., et al., Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics*. 2014; 13(2): 397-406.
10. Goyette, P., et al., Gene structure of human and mouse methylenetetrahydrofolate reductase (*MTHFR*). *Mamm Genome*. 1998; 9(8): 652-656.
11. Mattson, M.P. and T.B. Shea, Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. *Trends Neurosci*. 2003; 26(3): 137-146.
12. Dicker-Brown, A., et al., The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine- β -synthase: studies in hepatocytes. *Atherosclerosis*. 2001; 158(2): 297-301.
13. Gallistl, S., et al., Insulin is an independent correlate of plasma homocysteine levels in obese children and adolescents. *Diabetes care*. 2000; 23(9): 1348-1352.

14. Lajin, B., A. Alachkar, and A.A. Sakur, Triplex tetra-primer ARMS-PCR method for the simultaneous detection of MTHFR c. 677C> T and c. 1298A> C, and MTRR c. 66A> G polymorphisms of the folate-homocysteine metabolic pathway. *Mol Cell Probe*. 2012; 26(1): 16-20.
15. Chen, H., et al., MTHFR gene C677T polymorphism and type 2 diabetic nephropathy in Asian populations: a meta-analysis. *Int J Clin Exp Med*. 2015; 8(3): 3662.
16. Chehadeh, S.W.E.H., et al., Relationship between MTHFR C677T and A1298C gene polymorphisms and complications of type 2 diabetes mellitus in an Emirati population. *Meta gene*. 2016; 9: 70-75.
17. Cho, K., et al., Methylenetetrahydrofolate Reductase A1298C Polymorphism and Major Depressive Disorder. *Cureus*. 2017; 9(10).
18. Zhong, J.-H., et al., Methylenetetrahydrofolate reductase gene polymorphism and risk of type 2 diabetes mellitus. *PLoS One*. 2013; 8(9): 74521.
19. Nunes, M.K.S., et al., Hypermethylation in the promoter of the MTHFR gene is associated with diabetic complications and biochemical indicators. *Diabetol Metab Syndr*. 2017; 9(1): 84.
20. Ilhan, N., et al., The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. *Arch Med Res*. 2008; 39(1): 125-130.
21. Kheradmand, M., et al., Associations of MTHFR C677T polymorphism with insulin resistance, results of NURSE Study (Nursing Unacquainted Related Stress Etiologies). *J Diabetes Metab Disord*. 2017; 16(1): 22.
22. Miller, S., D. Dykes, and H. Polesky, A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988; 16(3): 1215.
23. You, F.M., et al., BatchPrimer3: a high throughput web application for PCR and sequencing primer design. *BMC bioinformatics*. 2008; 9(1): 253.
24. Davegårdh, C., et al., DNA methylation in the pathogenesis of type 2 diabetes in humans. *Mol Metab*. 2018.
25. Rönn, T. and C. Ling, DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes. *Epigenomics*. 2015; 7(3): 451-460.
26. Dicker-brown, A., et al., The effect of glucose and insulin on the activity of enzymes in homocysteine metabolism. *Diabetes*. 1999; 48(5): 135-135.
27. Raza, S.T., et al., Association between ACE (rs4646994), FABP2 (rs1799883), MTHFR (rs1801133), FTO (rs9939609) genes polymorphism and type 2 diabetes with dyslipidemia. *Int J Mol Cell Med*. 2017; 6(2): 121.
28. Raza, S.T., et al., Association of MTHFR and PPAR γ 2 gene polymorphisms in relation to type 2 diabetes mellitus cases among north Indian population. *Gene*. 2012; 511(2): 375-379.
29. Mtiraoui, N., et al., MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. *Diabetes Res Clin Pract*. 2007; 75(1): 99-106.
30. Yan, Y., et al., Methylenetetrahydrofolate reductase A1298C polymorphism and diabetes risk: evidence from a meta-analysis. *Renal failure*. 2014; 36(7): 1013-1017.
31. Zhou, B.-S., et al., Tagging SNPs in the MTHFR gene and risk of ischemic stroke in a Chinese population. *Int J mol Sci*. 2014; 15(5): 8931-8940.